Synthetic data only. Never enter patient information; nothing is sent or stored. For clinicians. Not FDA cleared.For licensed clinicians. Educational demonstration on synthetic data. Never enter real patient identifiers or protected health information: everything runs in your browser and nothing is sent or stored. Clinical decision support only; not FDA cleared; physician review is required.
CPE-007 · Risk modifiers
CV-07: Apolipoprotein B
Apolipoprotein B. Evaluates apoB ≥ 130 mg/dL.
Active rulePriority 5Cardio engine v1.0.0
Condition
- apoB ≥ 130 mg/dL
- OR triglycerides 150 to 499 or diabetes or metabolic syndrome with apoB not measured
What it reports
- apoB ≥130 is a risk enhancer
- apoB can clarify particle burden when triglycerides are raised
Diagnostic boundary
- A marker, not a target set by this rule.
Evidence
- EV-ACCAHA-CHOL-2018Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Circulation. 2019;139(25):e1082-e1143.Supports: Risk categories, risk enhancers, statin benefit groups and the coronary-calcium decision aid Very-high-risk ASCVD definition
- EV-NLA-2015Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1. J Clin Lipidol. 2015;9(2):129-169.Supports: apoB as a marker of atherogenic particle number, particularly with raised triglycerides
Cases where this rule fires
Open a case to see this rule fire with real inputs, then change the values until it stops.
Try Biod in your practice
The Clinical Intelligence Layer — transforming fragmented clinical information into structured intelligence for clinician review and action.